AI Model May Predict Toxicity Risk in Breast Cancer Surgery Populations
Investigators will assess the PRE-ACT tool’s ability to predict adverse effects such as skin and heart damage in a phase 3 trial.
Findings Ways to Embrace Work-Life Balance as a GU Oncologist
A long commute can significantly impact your work-life balance, according to Mary-Ellen Taplin, MD.
Incorporating New ASTRO Partial Breast Irradiation Guidelines Into Practice
A Miami Breast Cancer Conference presentation focused on how the new ASTRO partial breast irradiation guidelines could be incorporated into practice.
Finding Ways to Improve Outcomes in dMMR Gastroesophageal Cancer
Adrienne Bruce Shannon, MD, discussed ways to improve treatment and surgical outcomes for patients with dMMR gastroesophageal cancer.
Ivonescimab/Chemo Shows Promising Anti-Tumor Activity in NSCLC Subsets
Intracranial disease control with Ivonescimab plus chemotherapy appears encouraging in patients with non–small cell lung cancer and brain metastases.
FDA Issues CRLs for Odronextamab in R/R Follicular Lymphoma and DLBCL
The agency submits complete response letters based on the enrollment status of confirmatory trials for odronextamab in follicular lymphoma and diffuse large B-cell lymphoma.
Avutometinib Combo Yields Responses in Serous Ovarian Cancer Subgroups
Findings from the phase 2 RAMP 201 trial highlight responses with avutometinib/defactinib in those with KRAS-mutated low-grade serous ovarian cancer and other patient subgroups.
Becotarug/Osimertinib Yields Antitumor Activity in EGFR exon 12 NSCLC
A 50% objective response rate was observed when becotarug plus osimertinnib was combined to treat patients with EGFR exon 12 non–small cell lung cancer.
Imaging Agent May Help Detect Breast Cancer Tumors During Surgery
Barbara Smith, MD, PhD, spoke about the potential use of pegulicianine-guided breast cancer surgery based on reports from the phase 3 INSITE trial.
Forging a Path in Thoracic Surgery to Create a Stellar Career
Rian M. Hasson Charles, MD, MPH, FACS, has a first-of-its-kind role at Brigham and Women’s Hospital that will focus on health equity.
EU’s CHMP Recommends Enzalutamide Approval in Non-Metastatic HSPC
The positive opinion is supported by findings from the phase 3 EMBARK trial assessing enzalutamide in patients with biochemically recurrent prostate cancer.
Navigating GU Oncology in a Male-Dominated Field
Mary-Ellen Taplin, MD, spoke about working in genitourinary oncology and how she has maneuvered the field as a woman.
Updated ASCO Guidelines for Optimal Small Cell Lung Cancer Management
Practices are on the cusp of better understanding small cell lung cancer that in turn can help to advance treatment strategies for patients, says Gregory Peter Kalemkerian, MD.
Rezatapopt Yields Early Responses, Safety in Advanced Ovarian Cancer
Several patients with TP53 Y220C–mutated ovarian cancer experience tumor shrinkage following treatment with rezatapopt in the phase 1/2 PYNNACLE study.
The QOL Impact of Lymphedema After Breast Cancer
Lymphedema is a common adverse effect and may negatively impact a patient’s body image.
Perioperative Telemonitoring Yields “Encouraging” Results in GI Cancers
Patient-reported symptoms following surgery appear to improve with the use of perioperative telemonitoring, says Kelly M. Mahuron, MD.
Early Detection and Treatment of Lymphedema After Breast Cancer
Lymphedema is an adverse effect associated with breast cancer treatment, and patients should be monitored for these symptoms.
Managing Resected CRC Peritoneal Metastasis Following Recurrence
Treatment options in the refractory setting must improve for patients with resected colorectal cancer peritoneal metastasis, says Muhammad Talha Waheed, MD.
FDA Approves Mirvetuximab Soravtansine in FRα+ Ovarian Cancer
Data from the phase 3 MIRASOL trial support the full FDA approval of mirvetuximab soravtansine for those with folate receptor alpha–positive platinum-resistant ovarian cancer.
Adjuvant Atezolizumab Plus Chemo Does Not Add Survival Benefit in TNBC
The phase 3 IMpassion030 trial did not find a survival benefit when atezolizumab was added to chemotherapy after surgery for patients with triple-negative breast cancer.
Osimertinib/Chemo Yields Favorable OS Trend in EGFR-Mutated NSCLC
Treatment with osimertinib plus chemotherapy also shows a consistent survival benefit across prespecified NSCLC subgroups in the phase 3 FLAURA2 trial.
Primary End Points Not Met With Pembrolizumab/Olaparib in NSCLC Trial
The phase 3 KEYLYNK-006 trial did not meet the primary end points of progression-free and overall survival in patients with metastatic nonsquamous non–small cell lung cancer.
Studies Assessing Vaccines in Different Cancer Types Appear “Promising”
Cancer vaccines are a “cross-cutting approach” that may be applicable across several cancer types, according to Catherine J. Wu, MD.
Ide-Cel Earns European Approval in Triple-Class Exposed Multiple Myeloma
Data from the phase 3 KarMMa-3 trial support the approval of idecabtagene vicleucel for relapsed/refractory multiple myeloma in the European Union.
Nivolumab/Ipilimumab Significantly Improves OS in Advanced Liver Cancer
The safety of nivolumab plus ipilimumab among those with hepatocellular carcinoma in the CheckMate-9DW trial appears to be comparable with prior reports.
Data May Support Pembrolizumab/Chemo as New SOC in Endometrial Cancer
Although immature, overall survival data from the KEYNOTE-868 trial may support the use of pembrolizumab plus chemotherapy in patients with endometrial cancer.
No Major Racial Disparities Reported in Allogeneic Transplant Outcomes
Study authors note that access to multidisciplinary teams and transportation programs may help mitigate hematopoietic cell transplantation outcome disparities.
Dostarlimab/Chemo Yields “Unprecedented” OS in dMMR Endometrial Cancer
Dostarlimab plus chemotherapy appears to yield favorable overall survival in patients with mismatch repair proficient endometrial cancer.
Stereotactic Radiation Appears Effective in Primary Renal Cell Cancer
Findings from a phase 2 trial highlight an acceptable adverse effect profile and renal function with stereotactic ablative body radiotherapy in primary renal cell cancer.
Geographic/Financial Barriers to CAR T Therapy Exist in Hematologic Cancers
Findings suggest investigating an individualized monitoring period for stable patients with hematologic cancers to decrease financial and geographic barriers to CAR T-cell therapy.
